Endokrin Bozukluklarda Psikofarmakolojik Tedavi Seçimleri
Özet
Kronik psikiyatrik hastalıklarda (şizofreni, bipolar ve majör depresif bozukluk) sık kullanılan antipsikotik, antidepresan ve duygudurum düzenleyici ilaçların endokrin sistem (glukoz metabolizması, tiroid fonksiyonları, prolaktin ve sodyum düzeyleri) üzerindeki etkilerini inceleyen bu metinde, psikotrop ilaçların fiziksel komplikasyon ve metabolik hastalık risklerini artırabildiği belirtilmektedir. Depresyon ve diyabet komorbiditesinde antidepresanların glukoz homeostazına etkileri kritik olup; amitriptilin, mirtazapin ve paroksetin kilo alımıyla ilişkiliyken, fluoksetin ve sertralin insülin direncini azaltarak iyileşme sağlayabilir. Antipsikotikler ise dopamin D2 ve histamin H1 reseptör blokajı gibi mekanizmalarla kilo alımı ve Tip 2 diyabet riskini artırır; bu risk olanzapin ve klozapinde en yüksek, aripiprazol ve ziprasidonda en düşüktür. Ayrıca, lityum tedavisi özellikle kadınlarda klinik hipotiroidizm ve guatr gelişimine yol açabileceğinden düzenli TSH takibi gerektirir. Antipsikotiklerin yol açtığı hiperprolaktinemi ise amisülpirid ve risperidonda belirgin olup infertilite ve osteoporoz riski taşırken, klozapin ve aripiprazolda bu etki düşüktür. Son olarak, antidepresanlar (özellikle SSRİ'lar) ve antipsikotikler antidiüretik hormon salınımını etkileyerek hiponatremiye neden olabilir. Klinisyenlerin zihinsel ve fiziksel sağlık dengesini korumak için multidisipliner çalışması ve metabolik takipleri düzenli yapması önerilmektedir.
This text, which examines the effects of antipsychotic, antidepressant, and mood-stabilizing medications frequently used in chronic psychiatric disorders (schizophrenia, bipolar, and major depressive disorder) on the endocrine system (glucose metabolism, thyroid functions, prolactin, and sodium levels), states that psychotropic drugs can increase the risk of physical complications and metabolic diseases. In the comorbidity of depression and diabetes, the effects of antidepressants on glucose homeostasis are critical; while amitriptyline, mirtazapine, and paroxetine are associated with weight gain, fluoxetine and sertraline can provide improvement by reducing insulin resistance. Antipsychotics increase the risk of weight gain and Type 2 diabetes through mechanisms such as dopamine D2 and histamine H1 receptor blockade; this risk is highest with olanzapine and clozapine, and lowest with aripiprazole and ziprasidone. Additionally, lithium therapy requires regular TSH monitoring as it can lead to the development of clinical hypothyroidism and goiter, particularly in female patients. Antipsychotic-induced hyperprolaktinemia is prominent with amisulpride and risperidone, carrying risks of infertility and osteoporosis, whereas this effect is low with clozapine and aripiprazole. Lastly, antidepressants (especially SSRIs) and antipsychotics can cause hyponatremia by affecting antidiuretic hormone secretion. Clinicians are recommended to work multidisciplinary and perform regular metabolic monitoring to maintain the balance between mental and physical health.
Referanslar
Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World psychiatry. 2015;14(2):119-136.
Smith M, Hopkins D, Peveler R, et al. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry. 2008;192(6):406-411.
Organization WH. Diabetes Fact Sheet: World Health Organization. 2016.
Unwin N, Whiting D, Gan D, et al. International Diabetes Federation Diabetes Atlas. IDF Diabetes Atlas. 2009;4.
McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia research. 2005;80(1):19-32.
Van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. General hospital psychiatry. 2010;32(4):380-395.
Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues in clinical neuroscience. 2022.
Serretti A, Mandelli L, Laura M. Antidepressants and body weight: a comprehensive review and meta-analysis. The Journal of clinical psychiatry. 2010;71(10):979.
Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. American Journal of Psychiatry. 2009;166(5):591-598.
Raeder MB, Bjelland I, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. The Journal of clinical psychiatry. 2006;67(12):12989.
van Reedt Dortland AK, Giltay EJ, Van Veen T, et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatrica Scandinavica. 2010;122(1):30-39.
Deuschle M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Current opinion in psychiatry. 2013;26(1):60-65.
Ye Z, Chen L, Yang Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2011;6(7):e21551.
Lustman PJ, Freedland KE, Griffith LS, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes care. 2000;23(5):618-623.
Goodnick PJ, Kumar A, Henry JH, et al. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacology bulletin. 1997;33(2):261.
Lustman PJ, Clouse RE, Nix BD, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Archives of general psychiatry. 2006;63(5):521-529.
Lustman PJ, Williams MM, Sayuk GS, et al. Factors influencing glycemic control in type 2 diabetes during acute-and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes care. 2007;30(3):459-466.
Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Current drug safety. 2009;4(1):22-29.
Kadiroglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications. 2008;22(4):241-245.
Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30(1):21-26.
Sayuk GS, Gott BM, Nix BD, et al. Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion. Diabetes care. 2011;34(2):332-334.
De Hert M, Dekker J, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European psychiatry. 2009;24(6):412-424.
JBDS R. The Management of Diabetes in Adults and Children with Psychiatric Disorders in Inpatient Settings. Joint British Diabetes Societies and Royal College of Psychiatrists. 2017.
Mulligan K, McBain H, Lamontagne‐Godwin F, et al. Barriers and enablers of type 2 diabetes self‐management in people with severe mental illness. Health expectations. 2017;20(5):1020-1030.
Cohen D, Batstra M, Gispen-de Wied C. Immunological characteristics of diabetes in schizophrenia. Diabetologia. 2005;48(9):1941-1942.
Holt RI. Association between antipsychotic medication use and diabetes. Current diabetes reports. 2019;19(10):1-10.
Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity and Metabolism. 2009;11(7):665-679.
Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Jama. 2009;302(16):1765-1773.
Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacology & therapeutics. 2010;125(1):169-179.
Freyberg Z, McCarthy MJ. Dopamine D2 receptors and the circadian clock reciprocally mediate antipsychotic drug-induced metabolic disturbances. npj Schizophrenia. 2017;3(1):1-8.
Whicher CA, Price HC, Holt RI. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. European journal of endocrinology. 2018;178(6):R245-R258.
Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia research. 2010;123(2-3):225-233.
Hirsch L, Yang J, Bresee L, et al. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug safety. 2017;40(9):771-781.
Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophrenia bulletin. 2014;40(6):1385-1403.
Smith JW, Evans AT, Costall B, et al. Thyroid hormones, brain function and cognition: a brief review. Neuroscience & Biobehavioral Reviews. 2002;26(1):45-60.
Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology: the scientific basis of clinical practice: American Psychiatric Pub; 2008.
Bathla M, Singh M, Relan P. Prevalence of anxiety and depressive symptoms among patients with hypothyroidism. Indian journal of endocrinology and metabolism. 2016;20(4):468.
Gupta S, Saha PK, Mukhopadhyay A. Prevalence of hypothyroidism and importance of cholesterol estimation in patients suffering from major depressive disorder. Journal of the Indian Medical Association. 2008;106(4):240, 242-240, 242.
Davis J, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva endocrinologica. 2007;32(1):49-65.
Carvalho AF, Machado JR, Cavalcante JL. Augmentation strategies for treatment-resistant depression. Current opinion in psychiatry. 2009;22(1):7-12.
Khalil RB, Richa S. Thyroid adverse effects of psychotropic drugs: a review. Clinical neuropharmacology. 2011;34(6):248-255.
Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. International journal of bipolar disorders. 2016;4(1):1-10.
McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. The Lancet. 2012;379(9817):721-728.
Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. The Journal of clinical psychiatry. 2005;66(1):20986.
Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical endocrinology. 2011;74(2):141-147.
Kane JM, Meltzer HY, Carson Jr WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry. 2007;68(2):213-223.
Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry. 2009;70(10):14597.
Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. Journal of Psychopharmacology. 2008;22(2_suppl):98-103.
Mannesse CK, Van Puijenbroek EP, Jansen PA, et al. Hyponatraemia as an adverse drug reaction of antipsychotic drugs. Drug safety. 2010;33(7):569-578.
De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536-547.
